Search Results 261-270 of 17307 for Teratogenic
Participation eligibility · Has T4 tumors · Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:.
Patients must not be pregnant or nursing due to the potential teratogenic side effects of the protocol treatment. Women of child-bearing potential and men ...
Female patients who are pregnant, since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is ...
Pregnant or lactating women, or sexually active men or women not using effective contraception (risk for fetal defects from teratogenic chemotherapy and ...
mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative serum or ...
... teratogenic; women who are breastfeeding are also excluded. Prior allergic reaction or hypersensitivity to cetuximab or MEDI4736 (durvalumab) or any of ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
The purpose of this study is to investigate how abrupt loss of ovarian hormones following bilateral oophorectomy affects overall aging, physical performance ...
About this study. The purposes of this study are to determine whether maternal T cells are activated and expand after in utero intervention, ...
Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.